JP2023543835A5 - - Google Patents
Info
- Publication number
- JP2023543835A5 JP2023543835A5 JP2023519659A JP2023519659A JP2023543835A5 JP 2023543835 A5 JP2023543835 A5 JP 2023543835A5 JP 2023519659 A JP2023519659 A JP 2023519659A JP 2023519659 A JP2023519659 A JP 2023519659A JP 2023543835 A5 JP2023543835 A5 JP 2023543835A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025187326A JP2026015391A (ja) | 2020-09-30 | 2025-11-06 | 抗ｃｄ９４抗体及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063085932P | 2020-09-30 | 2020-09-30 | |
| US63/085,932 | 2020-09-30 | ||
| US202063088926P | 2020-10-07 | 2020-10-07 | |
| US63/088,926 | 2020-10-07 | ||
| PCT/US2021/052668 WO2022072508A1 (en) | 2020-09-30 | 2021-09-29 | Anti-cd94 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025187326A Division JP2026015391A (ja) | 2020-09-30 | 2025-11-06 | 抗ｃｄ９４抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023543835A JP2023543835A (ja) | 2023-10-18 |
| JP2023543835A5 true JP2023543835A5 (cg-RX-API-DMAC10.html) | 2024-10-07 |
| JP7812848B2 JP7812848B2 (ja) | 2026-02-10 |
Family
ID=80950868
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519659A Active JP7812848B2 (ja) | 2020-09-30 | 2021-09-29 | 抗ｃｄ９４抗体及びその使用方法 |
| JP2025187326A Pending JP2026015391A (ja) | 2020-09-30 | 2025-11-06 | 抗ｃｄ９４抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025187326A Pending JP2026015391A (ja) | 2020-09-30 | 2025-11-06 | 抗ｃｄ９４抗体及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11795228B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4221752A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7812848B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230104611A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021352981A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3197662A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL301764A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023003685A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022072508A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA202303966B (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250197505A1 (en) * | 2022-03-25 | 2025-06-19 | Dren Bio, Inc. | Anti-cd94 antibodies and methods of use thereof |
| CN116178552B (zh) * | 2022-12-30 | 2025-03-07 | 合肥天港免疫药物有限公司 | 抗cd94的抗体及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69030172T2 (de) | 1990-01-26 | 1997-06-19 | Immunomedics Inc | Impfstoffe gegen Krebs und Infektionskrankheiten |
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| WO2005105848A1 (en) | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for enhancing nk cell activity |
| RU2481356C2 (ru) | 2004-12-28 | 2013-05-10 | Иннейт Фарма | Моноклональные антитела против nkg2a |
| EP1934260B1 (en) * | 2005-10-14 | 2017-05-17 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| DK2038306T3 (en) | 2006-06-30 | 2015-03-09 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
| MX2010007935A (es) | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| MX342131B (es) | 2011-06-17 | 2016-09-14 | Novo Nordisk As | Eliminacion selectiva de celulas erosivas. |
| RU2017105425A (ru) * | 2014-08-28 | 2018-09-28 | Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины |
| AU2015316993B2 (en) | 2014-09-16 | 2021-03-18 | Innate Pharma | Treatment regimens using anti-NKG2A antibodies |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| WO2020205440A1 (en) | 2019-03-29 | 2020-10-08 | Dren Bio, Inc. | Methods of reducing large granular lymphocyte and natural killer cell levels |
-
2021
- 2021-09-29 EP EP21876402.5A patent/EP4221752A4/en active Pending
- 2021-09-29 CA CA3197662A patent/CA3197662A1/en active Pending
- 2021-09-29 IL IL301764A patent/IL301764A/en unknown
- 2021-09-29 WO PCT/US2021/052668 patent/WO2022072508A1/en not_active Ceased
- 2021-09-29 KR KR1020237014582A patent/KR20230104611A/ko active Pending
- 2021-09-29 AU AU2021352981A patent/AU2021352981A1/en active Pending
- 2021-09-29 MX MX2023003685A patent/MX2023003685A/es unknown
- 2021-09-29 JP JP2023519659A patent/JP7812848B2/ja active Active
- 2021-09-29 US US17/489,385 patent/US11795228B2/en active Active
-
2023
- 2023-03-29 ZA ZA2023/03966A patent/ZA202303966B/en unknown
-
2024
- 2024-11-26 US US18/961,026 patent/US20250197506A1/en active Pending
-
2025
- 2025-11-06 JP JP2025187326A patent/JP2026015391A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7366543B2 (ja) | Ｂｃｍａ結合分子及びその使用方法 | |
| JP6317788B2 (ja) | 抗ｏｘ４０抗体およびそれを使用する方法 | |
| EP3763387B1 (en) | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy | |
| JP5604311B2 (ja) | 疾患治療剤 | |
| CN113454119B (zh) | 抗btla抗体 | |
| JP2021525544A5 (cg-RX-API-DMAC10.html) | ||
| CN110662768B (zh) | 治疗性抗cd40配体抗体 | |
| US12227583B2 (en) | Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use | |
| JP2016513467A5 (cg-RX-API-DMAC10.html) | ||
| HUE028962T2 (en) | Active ingredient for treating disease | |
| CN102027017A (zh) | 一种治疗疾病的试剂 | |
| JP7843824B2 (ja) | 抗体および使用方法 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2024535692A5 (cg-RX-API-DMAC10.html) | ||
| JP2023517794A5 (cg-RX-API-DMAC10.html) | ||
| JP2024527576A5 (cg-RX-API-DMAC10.html) | ||
| JP2022527084A5 (cg-RX-API-DMAC10.html) | ||
| JP2024543385A5 (cg-RX-API-DMAC10.html) | ||
| US20250051440A1 (en) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling | |
| AU2023329055A1 (en) | Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic | |
| WO2022057910A1 (en) | Combination therapies targeting c5ar and pd-1/pd-l1 pathways | |
| JP2025510783A5 (cg-RX-API-DMAC10.html) | ||
| HK40087536A (en) | Anti-cd40 antibody combination treatment for cancer | |
| HK40045557A (en) | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use |